Inflammation of the pinn a can occ ur in conj unction with polychondritis and otitis externa. We describe a case of pinn eal inflammation that proved to be sa rcoidosis, and we discuss the otolaryngologic manifestations ofsarco idosis.
Introduction
Sarcoidosis is a co mmon multi system diso rder of unknow n etiology that ca n mimic disease processes such as polychondritis.' It ca n be se lf-limiting or progressive and relentless . Lesions are made up of noncaseatin g epithelioid and giant-ce ll granulomas.
Sarcoid osis can affect seve ral organs and tissues, most commonly the hilar lymph nodes, eyes, skin, and muco sal surfaces . Otolaryngolo gists might enco unter lesions that affect the nose, ton sils, larynx, trachea, nasopharynx, facial bone s, and paranasal sinu ses. i-' The ear is an uncommon site, alth ough involvement of the acou stic nerve manifesting as sensorineural deafn ess has been documerited ." Moreover, sarcoi dos is has been described at the site of ea rlobe pie rcin gs, usually in patient s with systemic sarcoidosis.' Sarcoid osis with externa l ea r manifestati on s is exceeding ly rare, but it should be co nsidered in the differential diagnosis of an acut ely inflamed externa l ear. In this article , we describe a case of pinn eal sar coidosis . pinna, which had been present for 4 months. Initi ally the swe lling was painl ess, but it had becom e ac utely tend er dur ing the preceding wee k. No associated otologic sy mptoms were noted . Th e pati ent co mplained of feelin g genera lly unwell , and he had noticed a significant weig ht loss ove r the preceding weeks. Examin ation revealed that the heli cal ca rtilage and pinna on the right side was inflamed and thickened and that the ove rlying skin was erythemato us and excoriated (figure I). Th e ENT exa minatio n was other wise norm al.
Case report
A blood test revealed that the patient ' s se rum angiotensinco nve rting enzyme (ACE) level was e leva ted, but other param eters wer e normal. Aut oimmune antibody testing was negative.
A biop sy was performed , and histol ogy of the speci men identifi ed extensive noncaseating and coal escent granulom as that were made up of macrophages , giant cells, and lymphocytes, findings that are typic al of sarcoidos is (figure 2). Spe cial stains for orga nisms that cau se granul omas, such as fungi and Mycobacterium tuberculosis, were negati ve. Th e underlyin g cartilage was normal. A chest xray showe d bilateral hilar lymphaden op ath y consistent with pulm on ary sarcoidosis. Th e patient was referred to a respiratory ph ysici an for further managemen t, and sarco idosis was co nfirmed on transbron chi al biop sy.
Discussion
Th e overall incid enc e of sarco idosis has been reported to range fro m I to 40 cases per 100,000 po pulation." In most patient s, the disease firs t man ifests between the ages of20 and 40 years.' More women are affect ed than men . Historically, Hutchin son is credited with the first descript ion of this disease in 1875 . 8 He named it Mortim er 's malady after his patient , a Mr s. Mortimer, who had the unique skin findings. In 1899 , Boeck describ ed the ski n mani festat ions in more detail, and he call ed the dise ase Boeck 's sarcoidosis.' He used the root word sarcoid in the name 
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For more information Circle 105 on Reader Service Card because he thought it was a cutaneous form of sarcoma. The Danish ophthalmologist Heerfordt described the triad of uveitis, parotid enlargement, and cranial nerve paresis in 1909.9 Schaumann described the pathologic findings in 1916. 10 Finally, there is a skin test for sarcoidosis that involves the use of a heat-killed suspension from the lymph nodes of known sarcoid patient s." Sarcoidosis can manifest in many ways, and otolaryngologists must maintain an appropriate level of suspicion. By definition, sarcoidosis is a systemic disease . Hilar lymphadenopathy is present in 90 % of cases, and head and neck manifestations are found in 10 to 15% of cases." Pulmonary symptoms often go unnoticed for some time and, as occurred in our case, it is the head and neck manifestations that prompt the patient to seek medical attention. Findings on chest x-ray are used for staging irrespective of extrapulmonary involvement. A stage I designation is assigned to patients who have evidence of hilar adenopathy; these patients have an exce llent prognosis, with a 60 to 80 % chance of spontaneous resolution." Stage II indicates hilar adenopathy with pulmonary infiltrates; stage II disease remits in 50 to 60 % of patient s.' Stage III indicates the presence of pulmonary infiltrates without adenopathy, and disease remits in fewer than 30% of patients." Otolaryngologic manifestations of sarcoidosis can be varied. The most common finding is cervical lymphadenopathy, and the second most common is skin lesions. " A variety of other conditions has been described as well, including lupus pernio, Hutchinson' s plaque, and papular sarco id. Sinonasal tract involvement has been reported in as many as 18% of cases." Oral cavity manifestations of sarcoid are extremely rare. Parotid gland involvement is usually bilateral and nontender and has been reported in as many as 6% of cases ." Neurologic symptoms occur in only 5% of cases , but they are the most common reason for otolaryngologic co nsultatio n.' Facial nerve palsies are the most common cranial nerve deficit, but any cranial nerve can be affected. The paresis can be either fluctuating or progressive in nature."Laryngeal sarcoid is present in I to 5% of all patients with sarcoidosis.' The supraglottic area is the most commonly affected site, but the subglottic region may also be involved. The true vocal folds are rarely affected. Localized pale edema, punctate submucosal nodules, and even a mass lesion have been described on laryngoscopy. 16 The differential diagnosis of sarcoidosis can be exhaustive, and the diagnosis depends to a certain extent on the sites affected and the clinical signs and symptoms. Diagnosis requires a thorough physical examination, chest xray, serologic testing, and tissue evaluation to rule out other granulomato us diseases. Therefore, it is important that biopsies in cases of possible sarco idosis be analyzed by fungal and mycobacterial cultures and stains. Noncaseating granulomas are the hallmark of sarco idosis. Serologic testing can support the diagnosis of sarcoidosis. No single test is diagnostic, but the serum ACE level is the most useful test. Serum ACE levels are elevated in 60% of patients with sarcoidosis .17The enzyme is concentrated in the pulmonary vasculature and is also found in broncho-pulmonary lavage fluid , serum, and cerebrospinal fluid . Th e ACE level is useful not so much for its diagnostic value as it is for its value as a measure of the "g ranuloma load" and as a marker of a patient' s respon se to therap y.
Although the cause or trigger of sarcoidos is remains unkn own , the pathogen esis of its many mani festations is becoming more fully understood. We do know that a specific age nt or trigge r stimulates local macrophages. The stimulated macrophages sec rete chem otactic facto rs such as Iymph okines, which then attract T-helper (T4) lymphocytes. The T4 cell s in turn stimulate antibody production by B lymphocytes. To geth er the acti vated macroph ages, B lymph ocytes, and antibodies form granuloma s in the affec ted tissue." Thi s overactive local immune respon se depl etes the systemic immune system, thu s crea ting an immunolog ica lly co mpromised state.
Many Before a treatment opti on for sarcoidos is is co nsidered, patient s wo uld ideally be observed for an init ial period durin g which no treatment is administered, because it is possibl e that the disease will resolve spontaneously." However , when pulm onary manifestations are present , treatment is generally required. Treatm ent of ex trapulmonary manifestations is required when deforming skin lesion s are present and in cases of neurologic, ocular, major organ , or aerodiges tive tract involvem ent. Oral steroids rema in the cornerstone of treatment , but there is no set protocol. Patient s are usually treated for at least 6 month s init ially. Th e ACE level or the ery throcyte sediment ation rate can be used to monit or the response to the medi cal reg imen. Local steroids , either as topi cal ointment s or as nasal spray s, can be of benefit in cas es of skin or nasal involvemen t. Th e prognosis for patient s who require treatm ent is goo d; more than 70 % of such patient s either imp rove or experie nce no further progression of their disea se. 7 Those with pro gressive disease can expe rience a relentl ess course that can end in death secondary to either respiratory or cardiac failure.
Volume 82, Number 12
